Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 12 Sept 2026Clinical review pending
Saved on this device
!
Brain emergency precedes prevention
An evolving neurological deficit, reduced consciousness or new haemorrhage needs acute stroke care before a preventive operation is scheduled.
Action: Activate the stroke pathway, image the brain and intracranial circulation, and involve stroke and vascular specialists immediately; do not let a theatre target delay reperfusion treatment.
Synopsis
Choose a time-sensitive carotid endarterectomy plan that preserves early stroke-prevention benefit while recognising neurological and haemorrhagic hazards.
Treat any ongoing or recurrent focal deficit through the hyperacute stroke pathway first; carotid timing never supersedes brain imaging or reperfusion assessment.
For a stable TIA or non-disabling stroke with indicated 50–99% NASCET stenosis, perform CEA as soon as safely feasible, preferably within 14 days of symptom onset.
Defer CEA or CAS after disabling stroke, infarction exceeding one third of the ipsilateral MCA territory, altered consciousness or intracranial haemorrhage until neurological and imaging reassessment supports safety.
Key red flags
Modified Rankin score at least 3, infarction exceeding one third of the ipsilateral MCA territory or altered consciousness supports deferring carotid intervention.
Stroke in evolution or crescendo TIAs despite treatment require urgent joint specialist review and may justify CEA within 24 hours in selected patients.
Recent intravenous thrombolysis increases bleeding risk; withhold antiplatelet and heparin treatment for the first 24 hours and consider delaying carotid intervention by six days.
Disabling infarct
Dense persistent deficit with modified Rankin score at least 3 suggests lower immediate benefit and higher haemorrhagic risk.
Large infarct burden
Infarction exceeding one third of the ipsilateral MCA territory supports deferral until radiological and neurological improvement.
Crescendo symptoms
Repeated carotid-territory TIAs or stroke in evolution despite treatment require urgent multidisciplinary assessment for possible CEA within 24 hours.
Investigation priorities
01
Urgent brain CT or MRIFirst step
Define infarct size, haemorrhage and evolving brain injury
Management branches
ManagementStandard early CEA pathway
Recent stable non-disabling carotid-territory event with indicated ipsilateral stenosis
Record the exact last-known symptom onset and neurological status, then refer urgently to a stroke-linked vascular service.
Confirm 50–99% NASCET-equivalent stenosis with duplex plus CTA, MRA or second expert duplex and review current brain imaging.
Key medicines
AspirinFor suspected TIA give 300 mg orally once daily immediately unless contraindicated; after ischaemic stroke give 300 mg within 24 hours once haemorrhage is excluded, continuing to 14 days or earlier definitive antithrombotic review.Confirm swallowing route and review active bleeding, hypersensitivity, severe aspirin dyspepsia, anticoagulation, thrombocytopenia and reperfusion treatment. The operating team must specify perioperative continuation or substitution; do not create delay through an unowned antiplatelet plan.
ClopidogrelWithin 24 hours after an eligible minor ischaemic stroke (NIHSS ≤3) or moderate-to-high-risk TIA (ABCD2 ≥4), the selected UK product uses an oral clopidogrel loading dose of 300 mg, followed by 75 mg daily. Combine with aspirin 75–100 mg daily for 21 days before continuing single antiplatelet therapy. These product eligibility criteria never justify delaying suspected-TIA referral; a named specialist protocol must govern antiplatelets when CEA is contemplated.The selected SmPC does not recommend DAPT when CEA, thrombectomy, thrombolysis or anticoagulation is planned. Avoid in active bleeding or severe hepatic impairment; review other bleeding medicines and CYP2C19 inhibitors, especially omeprazole and esomeprazole.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 12 Sept 2026; clinical approval remains outstanding.